64988-69-8

Basic information

• Product Name: 5-(chloromethyl)-3-ethylisoxazole
• Synonyms: 5-(chloromethyl)-3-ethylisoxazole;isoxazole, 5-(chloromethyl)-3-ethyl-;5-(chloromethyl)-3-ethylisoxazole(SALTDATA: FREE);5-(chloromethyl)-3-ethyl-1,2-oxazole
• CAS NO: 64988-69-8
• Molecular Formula: C₆H₈ClNO
• Molecular Weight: 145.58682
• Mol File: 64988-69-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 228.5°C at 760 mmHg
• Flash Point: 92°C
• Appearance: /
• Density: 1.155g/cm³
• Vapor Pressure: 0.11mmHg at 25°C
• Refractive Index: 1.482
• PKA: -2.01±0.20(Predicted)
• CAS DataBase Reference: 5-(chloromethyl)-3-ethylisoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(chloromethyl)-3-ethylisoxazole(64988-69-8)
• EPA Substance Registry System: 5-(chloromethyl)-3-ethylisoxazole(64988-69-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 64988-69-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H8ClNO/c1-2-5-3-6(4-7)9-8-5/h3H,2,4H2,1H3

Upstream product

• 14716-90-6 (3-ethylisoxazol-5-yl)methanol 
• 627-39-4 propionaldehyde oxime 
• 624-65-7 2-propynyl chloride 
• 64988-78-9 5,6-dichloro-hex-4-en-3-one 

Downstream Products

• 942519-63-3 (3-ethylisoxazol-5-yl)-N-methylmethanamine 
• 942423-94-1 benzhydrylidene-[1-(2,3-dichloro-phenyl)-2-(3-ethylisoxazol-5-yl)-ethyl]-amine 
• 478016-03-4 3-ethyl-5-(isothiocyanatomethyl)isoxazole 

Relevant articles and documents

HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS

Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.

Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents

A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities. They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values. They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells. Among the compounds studied, 7 showed the most potent activity of growth inhibition (IC50 17-1711 nM) in several human cancer cells. Given orally, compounds 7 and 13 dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells. N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.